ClinicalTrials.Veeva

Menu

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

J

Juno Therapeutics

Status and phase

Enrolling
Phase 1

Conditions

Multiple Myeloma

Treatments

Drug: Alnuctamab
Drug: Iberdomide
Drug: Mezigdomide
Drug: BMS-986393

Study type

Interventional

Funder types

Industry

Identifiers

NCT06121843
CA088-1005

Details and patient eligibility

About

The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).

Enrollment

111 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • History of relapsed and/or refractory multiple myeloma (RRMM) treated with at least 3 (Part 1 and Part 2) or at least 1 but not greater than 3 prior anti-myeloma treatment regimens (Part 2)
  • Measurable multiple myeloma (MM)
  • Eastern Cooperative Oncology Group performance status of 0-1

Exclusion criteria

  • Condition that confounds the ability to interpret data from the study
  • Known active or history of central nervous system (CNS) involvement of MM

Note: Other protocol-defined inclusion/exclusion criteria apply

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Sequential Assignment

Masking

None (Open label)

111 participants in 3 patient groups

Arm A: BMS-986393 + Alnuctamab
Experimental group
Treatment:
Drug: BMS-986393
Drug: Alnuctamab
Arm B: BMS-986393 + Mezigdomide
Experimental group
Treatment:
Drug: BMS-986393
Drug: Mezigdomide
Arm C: BMS-986393 + Iberdomide
Experimental group
Treatment:
Drug: BMS-986393
Drug: Iberdomide

Trial contacts and locations

19

Loading...

Central trial contact

First line of the email MUST contain NCT # and Site #.; BMS Study Connect Contact Center www.BMSStudyConnect.com

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems